FOGAL CHRISTOPHER E
Known title: DirectorCIK: 0001200665
FOGAL CHRISTOPHER E's purchase track record
FOGAL CHRISTOPHER E has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/2/2023 | SBCF | $49K | +24.2% | +4.2% | +1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SBCF | ▲ Buy | Grant | 2,015 | $70K | 7/31/2026 | View on chart |
| SBCF | ▲ Buy | Option Exercise | 3,419 | $49K | 11/19/2025 | View on chart |
| SBCF | ▲ Buy | Grant | 2,218 | $63K | 7/31/2025 | View on chart |
| SBCF | ▲ Buy | Grant | 848 | $25K | 12/10/2024 | View on chart |
| SBCF | ▲ Buy | Grant | 2,245 | $63K | 7/31/2024 | View on chart |
| SBCF | ▲ Buy | Grant | 2,529 | $62K | 7/31/2023 | View on chart |
| SBCF | ▲ Buy | Open Market | 2,385 | $49K | 5/2/2023 | View on chart |
| SBCF | ▲ Buy | Grant | 1,747 | $63K | 7/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Seacoast Banking (SBCF) featured in analyst rating and rate outlook
Recent coverage highlighted Seacoast Banking as one of several regional banks that could see better performance if interest rates remain elevated. At the same time, Raymond James kept an Outperform view on the stock but adjusted its price target down to $36. The combination suggests analysts see potential upside but are moderating expectations amid the current rate environment.
Seacoast Banking (SBCF) featured in analyst rating and rate outlook. Recent coverage highlighted Seacoast Banking as one of several regional banks that could see better performance if interest rates remain elevated. At the same time, Raymond James kept an Outperform view on the stock but adjusted its price target down to $36. The combination suggests analysts see potential upside but are moderating expectations amid the current rate environment.